1Lun·

Share assessment

How do you do?

Here are a few stocks that I currently have on my watchlist. I have already bought a few tranches.

$TGT (+2,04 %)
$PEP (-5 %)
$NOVO B (+1,51 %)
$UPS (+0,77 %)

I think they are all quality companies and they also pay a dividend.

Novo Nordisk is possibly associated with more growth and the other three stocks are rather boring. However, I think the demand for the products and services will definitely not decrease.

I would be interested to know what you think of the companies mentioned. Do you have any of them on your watchlist, are you invested or do you want to get in? 😊👍🏻

12 Comentarios

D.S.@Cato_Bamboo

1Lun

At $NOVO B you actually have "more" growth, unfortunately in the wrong direction........... I liquidated 50% of my position yesterday.

•

Thommy98@Thommy98

1Lun

@Cato_Bamboo what do you mean :D they grow by 20% in 25 according to Factset.

•

D.S.@Cato_Bamboo

1Lun

@Thommy98 Never 👎

••

Homer@Simpson

1Lun

If a share is not included in the Ultimate Homer, then I don't think much of it 😁

•

Sebi@Seebi

1Lun

don't fall for the novo nonsense. Just because the share has fallen sharply does not mean that it is now buy the dip😀 In general, I would leave the companies on the watchlist for now, they are in good hands for the time being

•

Earnus@Earnus

1Lun

@Marcelxy As you have already done, I would tend to go to $NOVO B for the companies presented. To put it bluntly: Diabetes and obesity will continue to exist. I personally found the sell-off after the last study results too exaggerated. In my opinion, this could just as quickly swing in the other direction. You also have to keep an eye on the cooperation with $HIMS.

Of course, $NOVO B is not doing so well at the moment, but there are always new opportunities to buy. In any case, you have to be patient.

•

Sebi@Seebi

1Lun

@Earnus things are not going well and you buy more? ok. With the hope that things will pick up again. Diabetes overweight, of course good arguments, but others are almost better and cheaper 😄 There is absolutely no justified reason to break out at the top, on the contrary, there is plenty of room for improvement with all the side effects

••

Earnus@Earnus

1Lun

@Seebi I understand your point of view, but I actually see it somewhat differently. The biggest competitor of $NOVO B is $LLY - this applies to the diabetes division and slimming products. $PFE has been discontinued, at least in this market phase. Have I forgotten another company? I'm leaving out $HIMS for now, as they were only allowed to help out temporarily on the US market due to a bottleneck.

The sell-off at $NOVO B is mainly due to the 'weak' study results of a new weight loss product. Here, too, the efficacy hardly differed from that of $LLY. Now one can say that this speaks for $LLY. However, research will continue and for this reason I see a good risk/reward potential at the current prices. The figures for $NOVO B
are still intact and the diabetes division is also doing well.

If anything, I see geopolitical tensions as a greater risk, as the US market for $NOVO B is not unexciting.
It also depends on the purchase price - the share price fluctuates between just under €70 and €85. If you're not planning for the long term, that's also an opportunity.

•

Sebi@Seebi

1Lun

@Earnus I took the easy way out to explain to you in detail why I was cautious about novo.
Chatgpt has summarized it wonderfully;

Novo Nordisk is one of the largest and best-known companies in the biopharmaceutical sector, particularly in the areas of diabetes treatment and hormone therapies. Nevertheless, there are some weaknesses and potential risks that investors should be aware of:

Dependence on a few products : Novo Nordisk relies heavily on a few products, particularly insulin and GLP-1 agonists (such as Ozempic and Wegovy). Should there be problems with marketing approval, efficacy or competition from generics or biosimilars, the company could be severely affected.

Regulatory risks : As a globally active company, Novo Nordisk has to overcome numerous regulatory hurdles in various countries. Changes in regulatory requirements or delays in the approval of new drugs could impair the company's growth opportunities.

Competition from generics and biosimilars : There is growing competition from generic and biosimilar products, particularly in the area of insulin production. These can increase price pressure and reduce the company's margins.

Dependence on the USA : A significant proportion of Novo Nordisk's sales come from the USA. Political and economic uncertainties, such as changes in healthcare policy or the insurance system, could affect the sale of medicines and the company's profitability.

Research and development Insufficient innovation could hamper future growth: Novo Nordisk invests heavily in research into new drugs, but as with any pharmaceutical company, there is no guarantee of success. Failures in clinical trials or an insufficient pipeline of innovative products could jeopardize future growth projections.

Price regulation and public perception : Given the high prices of insulin and other drugs, the company could suffer from public pressure or regulatory intervention requiring price cuts or a review of its business practices.

Why should you be cautious? Investors should be cautious about Novo Nordisk because the pharmaceutical industry in general is exposed to high risks - from regulatory problems to increasing competition. If the company is negatively affected in any of the above areas, this could have a major impact on the share price and profitability. A high market capitalization means that even small changes in the market or regulation could have a strong impact.

••

Earnus@Earnus

1Lun

@Seebi I respect your opinion. But in general, anyone investing in the pharmaceutical industry should always be aware of the increased volatility anyway - but that also applies to the stock market. I stand by my view that $NOVO B still offers the greatest potential in the above selection. The only biggest risk for me is the sales market in the USA and possible regulations by Trump or his congenial health minister. But when it comes to investing, everyone is ultimately allowed to follow their own strategy. Nevertheless - and I mean this seriously - thank you for your detailed approach.

•

Tenbagger2024@Tenbagger2024

1Lun

These four companies come from very different sectors. Novo also comes from Europe. You should also look at which sector and which country is still underweight in your portfolio.

••

finanzperpetuum@finanzperpetuum

3Semana

Novo stood at around €28 in Jan 21. Wegovy was approved in 2022 and until then it wasn't a chip store either. So in 4 years as of today, we have seen an annual return of around 25%, which is not too bad. The peak was just a bit too much of a good thing. At some point you have to take a look at the valuation.

••